Amgen (AMGN) Stock Forecast & Price Target

$278.99 +1.86 (+0.67%)

As of 10:21 AM Eastern

Amgen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 23 Analyst Ratings

Sell
2

Hold
12

Buy
9

Based on 23 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 23 analysts, 2 have given a sell rating, 12 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for AMGN.

Consensus Price Target

$307.82
10.33% Upside

According to the 23 analysts' twelve-month price targets for Amgen, the average price target is $307.82. The highest price target for AMGN is $383.00, while the lowest price target for AMGN is $195.00. The average price target represents a forecasted upside of 10.33% from the current price of $278.99.

Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

AMGN Analyst Ratings Over Time

Type	Current Forecast 6/30/24 to 6/30/25	1 Month Ago 5/31/24 to 5/31/25	3 Months Ago 4/1/24 to 4/1/25	1 Year Ago 7/1/23 to 6/30/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)
Hold	12 Hold rating(s)	12 Hold rating(s)	9 Hold rating(s)	10 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$307.82	$309.22	$314.04	$307.35
Forecasted Upside	10.33% Upside	7.73% Upside	2.32% Upside	-1.63% Downside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amgen Stock vs. The Competition

Type	Amgen	Medical Companies	S&P 500
Consensus Rating Score	2.35	2.81	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	11.07% Upside	8,529.95% Upside	12.42% Upside
News Sentiment Rating	Positive News See Recent AMGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/27/2025	Piper Sandler 2 of 5 stars	David Amsellem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00	+17.02%
6/24/2025	William Blair 2 of 5 stars		Reiterated Rating	Outperform
6/24/2025	Cantor Fitzgerald 3 of 5 stars	C. Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00	+11.95%
5/20/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00	+4.29%
5/8/2025	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	H. Engel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Salim Syed Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$235.00 ➝ $280.00	+3.08%
5/2/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$319.00 ➝ $315.00	+13.68%
5/2/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight
5/2/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$324.00 ➝ $320.00	+14.33%
3/5/2025	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target		$294.00	-10.47%
Get the Latest News and Ratings for AMGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.
3/5/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underperform ➝ Underperform	$275.00 ➝ $294.00	-6.90%
2/5/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight
2/5/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
1/8/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$333.00 ➝ $298.00	+13.71%
1/2/2025	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	$310.00	+18.94%
11/27/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$305.00 ➝ $285.00	+1.78%
11/27/2024	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$200.00 ➝ $195.00	-30.36%
11/27/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$349.00 ➝ $302.00	+7.85%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/12/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$380.00 ➝ $380.00	+28.07%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$381.00 ➝ $383.00	+20.14%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$380.00	+18.15%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$300.00 ➝ $315.00	-0.48%
9/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform ➝ Underperform	$215.00 ➝ $215.00	-31.92%
9/16/2024	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$380.00 ➝ $380.00	+22.53%
6/27/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$300.00 ➝ $340.00	+8.87%
5/3/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$336.00 ➝ $355.00	+12.91%
3/28/2024	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
2/7/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$313.00 ➝ $350.00	+10.73%
12/21/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$264.00 ➝ $320.00	+16.29%
10/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$270.00	-3.69%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$320.00	+25.98%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$220.00 ➝ $200.00	-10.66%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:21 AM ET.

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 28, 2025. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

Here are some ways that investors could benefit from investing in Amgen Inc.:

The current stock price is around $277, which may present a buying opportunity for investors looking for value in the biotech sector.
Amgen Inc. has a strong market capitalization of approximately $149 billion, indicating a solid position in the industry and potential for growth.
Recent institutional investments, such as Sequoia Financial Advisors LLC increasing its holdings by 3.6%, suggest confidence in the company's future performance.
The company has a relatively low beta of 0.51, indicating that its stock is less volatile compared to the overall market, which may appeal to risk-averse investors.
Amgen Inc. has a diverse portfolio of medical research products, which can help mitigate risks associated with reliance on a single product line.

Amgen
Bear Case

Investors should be bearish about investing in Amgen Inc. for these reasons:

The stock has recently experienced a decline of about 0.7%, which may indicate short-term challenges or market sentiment issues.
Amgen Inc. has a high debt-to-equity ratio of 8.70, suggesting that the company relies heavily on debt financing, which can be risky if not managed properly.
Insider ownership is relatively low at 0.76%, which may raise concerns about alignment between management and shareholder interests.
Recent insider selling, such as the sale of 1,500 shares by a senior vice president, could signal potential issues or lack of confidence in the company's near-term prospects.
With 76.50% of the stock owned by institutional investors, there may be less room for retail investors to influence company decisions or benefit from price movements.

AMGN Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $307.82, with a high forecast of $383.00 and a low forecast of $195.00.
: 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 12 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
: According to analysts, Amgen's stock has a predicted upside of 10.33% based on their 12-month stock forecasts.
: Over the previous 90 days, Amgen's stock had 1 downgrade by analysts.
: Amgen has been rated by research analysts at Cantor Fitzgerald, Erste Group Bank, Guggenheim, Mizuho, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, UBS Group, and William Blair in the past 90 days.
: Analysts like Amgen less than other "medical" companies. The consensus rating for Amgen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:AMGN) was last updated on 6/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amgen (AMGN) Stock Forecast & Price Target